NDC 50090-0139-01 - Hydralazine Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-0139
- Requested NDC
- 50090-0139-01
- Package NDCs from labels
- 50090-0139-4, 50090-0139-1, 50090-0139-3, 50090-0139-0, 50090-0139-2, 50090-0139-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2025-12-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Hydralazine Hydrochloride - A-S Medication Solutions | A-S Medication Solutions | 2025-12-05 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-0139-0 | Hydralazine Hydrochloride | 100 in 1 BOTTLE | TABLET | 100 | 31 | |
| 50090-0139-1 | Hydralazine Hydrochloride | 60 in 1 BOTTLE | TABLET | 60 | 31 | |
| 50090-0139-2 | Hydralazine Hydrochloride | 180 in 1 BOTTLE | TABLET | 180 | 31 | |
| 50090-0139-3 | Hydralazine Hydrochloride | 90 in 1 BOTTLE | TABLET | 90 | 31 | |
| 50090-0139-4 | Hydralazine Hydrochloride | 270 in 1 BOTTLE | TABLET | 270 | 31 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-0139 | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS] | 27 | Current NDC, Legacy NDC, 5 package rows | 20230623_f16f1d87-f9e6-4555-9baf-26ff17cb1d28.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-0139-1 | EA - Each | 50090-0139 | 909665fd-356e-4420-8e10-37dd14f0f8e2 | 1 | 2021-05-05 |
| 50090-0139-2 | EA - Each | 50090-0139 | 504f769f-0c65-482e-baf1-0ffe9f65ff64 | 1 | 2021-05-05 |
| 50090-0139-3 | EA - Each | 50090-0139 | 60697e64-520d-4838-9848-a18d3df45535 | 1 | 2021-05-05 |
| 50090-0139-4 | EA - Each | 50090-0139 | 8460a52a-9377-4614-aab4-ed33eb38415c | 1 | 2021-05-05 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| HYDRALAZINE HYDROCHLORIDE | ACTIVE INGREDIENT | FD171B778Y | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 | |
| HYDRALAZINE | ACTIVE MOIETY | 26NAK24LS8 | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 | |
| ANHYDROUS LACTOSE | INACTIVE INGREDIENT | 3SY5LH9PMK | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 | |
| FD&C YELLOW NO. 6 | INACTIVE INGREDIENT | H77VEI93A8 | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO | INACTIVE INGREDIENT | 5856J3G2A2 | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | HYDRALAZINE HYDROCHLORIDE TABLET [A-S MEDICATION SOLUTIONS LLC] | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Hydralazine Hydrochloride | HYDRALAZINE HYDROCHLORIDE | Aphena Pharma Solutions - Tennessee, LLC | d9892176-d4a6-4edb-92b9-5f56243f3d22 | 2016-06-13 | Warnings, Adverse reactions | 905222 FD171B778Y |
| Hydralazine Hydrochloride | HYDRALAZINE HYDROCHLORIDE | Teva Pharmaceuticals USA, Inc. | ddbbdb09-3202-42d7-bbb0-08331dde2f54 | 2016-02-29 | Warnings, Adverse reactions | 905225 905199 905395 905222 FD171B778Y |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.